The pathogenesis of diabetic vascular complications in the eye and kidney of humans is still not clear. There is evidence that glomerular filtration rate and renal plasma flow increase during poor metabolic control in patients with Type I (insulin-dependent) diabetes mellitus [1±3]. Several authors have also observed increased retinal and choroidal blood flow in patients with early diabetes [4±8], although there is some evidence of decreased ocular perfusion [9±10]. It has been suggested that this hyperperfusion in the kidney and the eye could predispose patients to develop vascular complications in these organs [11±14].
lin could also cause vasodilation [17] . The combined effects of insulin and glucose have been studied locally in the human forearm [18, 19] but no data are available for the eye and kidney of humans.
We investigated renal and ocular haemodynamic responses to hyperglycaemia at different plasma insulin concentrations. Renal plasma flow (RPF), glomerular filtration rate (GFR) and pulsatile choroidal blood flow were measured using the paraaminohippurate (PAH) method, the inulin method and laser interferometric measurement of fundus pulsation, respectively.
Subjects and methods
The studies were done according to the GCP guidelines and were approved by the ethics committee of the Vienna University School of Medicine. In the pilot study 8 healthy men volunteers were studied (age range 19±28 years). The main studies were carried out in 18 healthy men volunteers (age range: 21±35, means SD: 24.2 4.2). The study was explained to all volunteers who gave their written consent before participating. Each subject underwent screening that included medical history and a physical examination, a 12-lead electrocardiogram, a complete blood count, activated partial thromboplastin time, thrombin time, fibrinogen, clinical chemistry (sodium, potassium, creatinine, uric acid, glucose, cholesterol, triglycerides, alanine aminotransferase, aspartate transcarbamylase, g-glutamyltransferase, alkaline phosphatase, total bilirubin, total protein), hepatitis A, B, C and HIV-serology, urine analysis, urine drug-screening, and an oral glucose tolerance test (OGTT). Subjects were excluded if any abnormality was found except when the investigators considered the abnormality to be clinically irrelevant. Furthermore an ophthalmic examination, including slit lamp biomicroscopy and indirect funduscopy, was carried out. Inclusion criteria were normal ophthalmic findings and ametropia of 3 diopters or less.
Pilot study. To investigate potential haemodynamic effects of intravenous low dose somatostatin on renal and ocular blood flow a pilot study was carried out. Eight healthy subjects were included in this study and received an infusion of 0.1 mg/kg/min somatostatin (UCB Pharma, Vienna, Austria) over 180 min in an open design. RPF, GFR and ocular fundus pulsation amplitude (FPA) were measured every 60 min during the study.
Study design.
Two different studies were carried out. In protocol A, the haemodynamic effects of hyperglycaemic insulin clamps were investigated (n = 9). In protocol B, the haemodynamic effect of hyperglycaemic insulin clamps were studied during simultaneous inhibition of endogenous insulin secretion by somatostatin (n = 9). Both studies followed a randomised balanced 3-way cross-over design with washout periods of at least 4 days between trial days. The study schedule is given in Fig. 1 . Subjects received the following treatment on separate study days:
Treatment A: Placebo, glucose (at a rate to maintain glucose plasma levels at 5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l, respectively) Treatment B: 1 mU/kg/min Insulin, glucose (glucose plasma levels at 5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l, respectively) Treatment C: 2 mU/kg/min Insulin, glucose (glucose plasma levels at 5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l, respectively) Drugs. The following drugs were given intravenously:
Insulin (Huminsulin, Lilly; Fegersheim, France) 1 or 2 mU/ kg/min, infused over 180 min.
Glucose (glucose 20 %, Leopold Infusionsflaschen, Leopold Pharma, Linz, Austria) at a rate appropriate to maintain plasma glucose concentrations at 5.6 mmol/l, 11.1 mmol/l, 16.7 mmol/l, respectively. A maximum deviation of approximately 20 % was allowed for plasma glucose during the euglycaemic and hyperglycaemic insulin clamps.
Somatostatin (UCB Pharma, Vienna, Austria) 0.1 mg/kg/ min, infused over 180 min.
KCl (Kaliumchlorid Leopold 20 % Infusionszusatz, Leopold Pharma, Linz, Austria) at a rate of 10 mmol/h (if indicated).
Paraaminohippurate (PAH, Aminohippurate Sodium, MSD, West Point, Penn., USA) 8 mg/kg bolus, continuous infusion to attain 0.02 mg/ml PAH plasma concentration over 225 min at an estimated clearance of 750 ml/min.
A. Luksch et al.: Haemodynamic effects of insulin and glucose 96 Fig. 1 . Study schedule. Three study days were scheduled for each subject. Day A: Placebo + glucose; day B: Insulin (1 mU/ kg/min) + glucose; day C: Insulin (2 mU/kg/min) + glucose. In protocol B endogenous insulin secretion was blocked by somatostatin Inulin (Laevosan, Linz, Austria) 37.5 mg/kg bolus, continuous infusion to attain 0.25 mg/ml plasma concentration over 225 min at an estimated clearance of 140 ml/min.
Physiologic saline solution as placebo, infused over 180 min.
Study protocol. Before trial days subjects fasted overnight. When steady state conditions were reached ± verified by repeated blood pressure measurements during the resting period ± PAH and inulin infusions were started. After 45 min baseline measurements were done. These were carried out in a predetermined order (blood sampling, fundus pulsation measurement, blood pressure and pulse rate). The time schedule of measurements is shown in Fig. 1 . All haemodynamic measurements were carried out in the last 10 min of each plasma glucose concentration. Heart rate and real time ECG were measured continuously during drug treatment.
Study methods. Insulin clamps: Euglycaemic and hyperglycaemic insulin clamps were done as described previously [20] . Each clamp was started with a primed infusion of insulin for 8 min followed by a constant infusion rate of either 1 mU/kg/ min or 2 mU/kg/min. Somatostatin was only infused in the second study (protocol B). If necessary, potassium was infused to prevent hypokalemia. Glucose was infused at the rate needed to maintain the blood glucose at the required concentrations. For this purpose glucose concentration was measured using arterialized venous blood samples, which were drawn every 5 min from the contralateral arm placed in a heating box. Glucose plasma concentrations were measured using a glucose analyzer (Beckman Glucose Analyzer 2, Beckman Instruments Inc, Fullerton, Calif., USA). Insulin and C-peptide plasma concentrations were measured by routine laboratory procedures at scheduled time points.
We measured blood pressure, pulse rate, ECG and Mean arterial blood pressure (MAP) on the upper arm using an automated oscillometric device. The pulse rate was automatically recorded using a finger pulse-oxymetric device. The ECG and heart rate were monitored using a standard 4 lead device (HP-CMS patient monitor, Hewlett Packard, Palo Alto, Calif., USA).
PAH technique: RPF was assessed using the PAH plasma clearance method [21] . We measured PAH-plasma concentrations at baseline and during drug administration at scheduled time points by photometric analysis.
Inulin technique: GFR was assessed using the inulin plasma clearance method [21] . We measured inulin-plasma concentrations at baseline and during drug administration at scheduled time points using a commercially available kit (Laevosan, Linz, Austria).
Fundus pulsations: We assessed pulse synchronous pulsations of the ocular fundus by means of laser interferometry on the subject's right eye according to the method described previously [22] . The eye is illuminated by a beam from a single mode laser diode with a wavelength (l) of 783 nm. The light is reflected at the front side of both the cornea and the retina. The beam focus at the fundus has a diameter of 20±50 mm.
The reflection from the posterior segment probably occurs because of the retinal pigment epithelium or Bruch's membrane. The two re-emitted waves produce interference fringes which can be used to calculate the distance changes between the cornea and retina during a cardiac cycle. Distance changes between the cornea and retina are reflected in variations in the interference order (DN(t)). Changes in the interference order can be assessed by counting the fringes moving inwards and outwards during the cardiac cycle. Changes in optical distance (DL(t)), corresponding to the cornea-retina distance changes, can then be calculated using DL(t) = DN(t).l/2. The maximum distance change is called FPA and measures the local pulsatile blood flow [23] . The short-term and day-to-day variability of the method is small, allowing even small changes in local pulsatile blood flow to be detected [22] . The macula, where the retina lacks vasculature, was chosen to be measured to obtain information on the choroidal blood flow.
Data analysis. For data description haemodynamic parameters were expressed as per cent change from baseline (D%). Statistical analysis was done using absolute values. The effect of somatostatin in the pilot experiment was assessed by Friedman ANOVA. Effects of insulin and glucose on haemodynamic parameters were analysed by repeated measure ANOVA. A p value of less than 0.05 was considered significant. For data description, values are given as means SD.
Results
Pilot study. The results of the pilot study are presented in Table 1 . Somatostatin did not influence blood pressure or pulse rate and had no effect on FPA. Somatostatin infusion, however, caused a decrease in RPF (±12 5 %; p < 0.001 vs baseline) and a less pronounced decrease in GFR (±6 3 %, p < 0.001 vs baseline).
Protocol A. The baseline levels of all outcome variables for the three study days are shown in Table 2 . Insulin on its own did not affect the blood pressure or pulse rate (Table 3 ). The effects of insulin and glucose on renal and ocular haemodynamic variables are presented in Fig. 2 . Hyperinsulinaemia at normal plasma glucose concentrations increased RPF (1 mU/kg/min: 4 7 %, 2 mU/kg/min: 8 5 %; p = 0.04 versus placebo) but did not influence GFR. The effect of insulin during normoglycaemia on FPA was also significant (1 mU/kg/min: 9 4 %, 2 mU/kg/ min: 10 7 %; p = 0.02 versus placebo).
Hyperglycaemia did not affect the blood pressure or the pulse rate on the placebo day ( * Asterisks indicate significant differences from baseline (p < 0.05). Data are presented as means SD (n = 8) (11.1 mmol/l: 9 4 %, 16.7 mmol/l: 20 9 %; p < 0.001 vs baseline) and GFR (11.1 mmol/l: 7 5 %, 16.7 mmol/l: 9 8 %; p < 0.010 vs baseline) increased significantly when glucose plasma concentrations were in the hyperglycaemic range (Fig. 2) . Fundus pulsation amplitude (FPA) also increased during hyperglycaemia (11.1 mmol/l: 17 9 %, 16.7 mmol/l: 24 8 %; p < 0.001 vs baseline) and this effect was even more pronounced than in the kidney. Systemic, renal or ocular haemodynamic variables were not different between placebo and glucose infusion and co-infusion of insulin and glucose infusion (repeated measure ANOVA). At a glucose plasma concentration of 11.1 mmol/l RPF increased by 9 4 % during placebo, by 11 6 % during 1 mU/kg/ min insulin and by 11 10 % during 2 mU/kg/min insulin). The effects of 16.7 mmol/l glucose on RPF were similar during placebo and insulin infusion (Fig. 2) . The effects of hyperglycaemia on GFR and FPA were also similar during placebo and insulin. For example the effect of 16.7 mmol/l glucose on FPA was 24 8 % during placebo infusion, 28 10 % during 1 mU/kg/min and 30 11 % during 2 mU/kg/ min.
The effects of insulin and glucose infusion on insulin, glucose and C-peptide plasma concentrations are shown in Table 4 . Glucose plasma concentrations were in the range expected. In fact, mean glucose plasma concentrations were within 10 % of the target value for all infusion periods. Insulin plasma concentrations increased during all the study days. This increase was less pronounced on the placebo day than on the insulin days. The increase in insulin plasma concentrations during hyperglycaemia without insu- 6 Data are presented as means SD (each n = 9). All haemodynamic measurements were carried out in the last 10 minutes of each plasma glucose concentration. Data are presented as means SD (each n = 9). * Asterisks indicate significant differences from baseline (p < 0.05).
lin infusion was caused by an endogenous insulin release. The increase in C-peptide plasma concentrations provides further evidence for this.
Protocol B. The baseline levels of all outcome variables on the three study days are shown in Table 2 . Infusion of insulin and somatostatin did not influence blood pressure or pulse rate ( Table 3) . The renal and ocular haemodynamic variables during hyperglycaemic insulin clamps with somatostatin infusion are presented in Fig. 3 . Hyperinsulinaemia reversed the somatostatin-induced decrease in RPF (somatostatin alone: ±6 4 % somatostatin + 1 mU/kg/min: 1 5 %, somatostatin + 2 mU/ kg/min: 4 5 %; p = 0.003 vs somatostatin only). In contrast infusion of somatostatin + insulin had no effect on GFR. Insulin increased FPA significantly during somatostatin infusion (1 mU/kg/min: 10 5 %, 2 mU/kg/min: 13 7 %; p < 0.001 vs somatostatin only).
Hyperglycaemia did not affect blood pressure but decreased pulse rate (p = 0.003) on the placebo day where somatostatin only was given (Table 3) . RPF (somatostatin alone: ±6 4 %, 11.1 mmol/l: ±1 5 %, 16.7 mmol/l: 4 8 %; p = 0.003 vs baseline) and GFR (somatostatin alone: ±3 2 %, 11.1 mmol/l: 1 4 %, 16.7 mmol/l: 2 2 %; p = 0.002 vs baseline) increased significantly when plasma glucose concentrations increased as shown in Fig. 3 . FPA also increased during hyperglycaemia (FPA: 11.1 mmol/l: 9 9 %, 16.7 mmol/l: 16 13 %; p < 0.001 vs baseline).
The blood pressure, pulse rate and GFR were not different between the placebo/somatostatin/glucose infusion and the insulin/somatostatin/glucose infusion (repeated measure ANOVA). By contrast, the effects of glucose on RPF were more pronounced during hyperinsulinaemia than during placebo (p = 0.047). At 16.7 mmol/l glucose plasma concentration RPF increased by 4 8 % during placebo, by 6 10 % during 1 mU/kg/min insulin and by 11 7 % during 2 mU/kg/min insulin. The effects of glucose and insulin on RPF were additive during blockade of endogenous insulin release. The same phenomenon was observed for FPA (p = 0.020). A glucose plasma concentration of 300 mg/dl increased FPA by 16 13 % during placebo, by 23 9 % during 1 mU/kg/min insulin and by 25 8 % during 2 mU/ kg/min insulin. The effects of insulin and glucose infusion on insulin, glucose and C-peptide plasma concentrations are presented in Table 4 . Again, glucose plasma concentrations were near the target values during all infusion periods. In contrast to protocol A, no increase in insulin plasma concentrations could be detected for hyperglycaemia and exogenous insulin increased insulin plasma concentration to a much smaller extent. The decrease in C-peptide plasma concentrations confirmed the efficacy of the blockade with somatostatin.
Discussion
In our study insulin increased in RPF and FPA, which is in accord with previous studies [24±26]. In addition, plasma glucose had a significant influence on regional perfusion in the eye and the kidney. This is in agreement with a number of other studies on humans which indicate that rapid increase in plasma glucose induces vasodilation in the kidney and increases GFR [15, 27±29] . Some reports, however, indicate decreased renal plasma flow after the fast administration of glucose [30] . Several animal and human studies have shown that retinal blood flow increases with increasing plasma glucose in the eye [10, 16, 31] , but this is the first study to show choroidal vasodilation during hyperglycaemia in humans.
The main finding of our study is, however, that insulin and glucose exert additive vasodilator effects at the level of the renal and ocular vasculature. In the kidney and the choroid, the effects of hyperglycaemia were more pronounced during hyperinsulinaemia than during placebo because of additional vasodilation caused by insulin. In protocol A, however, the effect of the co-infusion of placebo and glucose infusion was almost equal to the effect of the co-infusion of insulin and glucose infusion. The pronounced increase in insulin plasma concentrations during hyperglycaemia due to an endogenous insulin release was most likely responsible for the results in this part of our study. Our data therefore show that glucose administered to healthy subjects causes vasodilator effects which are attributable to increases in plasma glucose as well as to increases in plasma insulin concentrations. During hyperinsulinaemic, hyperglycaemia plasma insulin concentrations increased to values of more than 400 mU/ml. This, however, did not increase renal or ocular blood flow, which indicates that the maximum vasodilatory on the concentration-response curve were reached. This agrees with a number of previous studies on different tissues [17, 26] .
The vasodilator effects of glucose and insulin could interact in a complex way. There is evidence that the vasodilator effect of glucose is more pronounced for retinal vasculature than for insulin, be- Data are presented as means SD (n = 9, each).
cause an insulin bolus reduces retinal blood flow in patients with Type I diabetes by decreasing glucose plasma concentrations [32] . The increase in regional blood flow during hyperinsulinaemia appears to be primarily mediated by nitric oxide [25, 33±35] . The mechanism underlying the response of vasodilation to rapid glucose infusion is less clear. It has been suggested that a change in NADH: NAD + ratio could be responsible for the glucose-induced vasodilation but this hypothesis has yet to be confirmed in human beings [36] . Interestingly, rapid hyperglycaemia blunts endothelium-dependent vasodilation in the human forearm [37] , which is most likely caused by the activation of protein kinase C [38] . Insulin and glucose could therefore exert complex interactions at the level of the vascular endothelium, but this needs to be investigated. In a previous study on rat skeletal muscle, hyperglycaemia modified the reaction of microvessels to insulin [39] . This effect was, however, not observed in the present in vivo study. A comprehensive characterisation of insulin and glucose on kidney functions was beyond the scope of our study. Interestingly, insulin increased RPF but had no effect on GFR. There is still no detailed characterisation of insulin's effects on the human kidney although increased renal plasma flow during hyperinsulinaemia could contribute to the decrease in proximal tubular sodium reabsorption, which could be a compensatory mechanism for insulin-induced sodium retention [24, 40] .
Our results could also be of relevance for understanding renal and ocular vascular disease in diabetes. In animal models, early structural and functional changes associated with diabetes include basement membrane thickening and increased local blood flow [41±43] . As mentioned, this is in accord with a variety of cross-sectional studies in human beings. Several hypothesis have tried to explain the association between increased perfusion and diabetic microvascular complications. Experimental evidence indicating that the onset and progression of diabetic nephropathy is linked to an increased intraglomerular capillary pressure [11] is compatible with a vasodilator effect of glucose on renal vessels. For ocular vasculature, it has been suggested that hyperperfusion could lead to endothelial damage and an altered autoregulation because of increased vessel wall shear stress [13, 14] . A major problem with extrapolating the present data to the pathologies observed in patients with diabetes is, however, that our data were obtained from short-term experiments. Whereas this study as well as reports from other groups clearly indicate vasodilator properties of insulin and glucose after fast exogenous administration no information on the long term haemodynamic effects is available. Further longitudinal studies, which focus on patients at the onset and on the very early stages of diabetes, are required to clarify this issue. Another important limitation of our study is that the experiments were not carried out in patients with Type I diabetes. The effects of hyperinsulinaemia on the absence and presence of high glucose need to be investigated for this group of patients. There is, however, some evidence that renal haemodynamic effects of hyperglycaemia are dependent on the stage of renal nephropathy [28] .
Our study also shows that low dose somatostatin reduces renal but not ocular blood flow. This is compatible with previous studies [44, 45] in healthy subjects. The mechanism underlying this renal vasoconstrictor action is, however, not known. It could well be, however, that the ability to inhibit insulin secretion contributes to reduced RPF during somatostatin administration. In addition, it has been suggested that somatostatin could have a direct effect on vascular smooth muscle through a calcium-dependent mechanism [46] .
The limitations of ocular fundus pulsation measurements have to be considered when discussing the results obtained in our study for the human choroid. There is evidence that FPA is an adequate measure of pulsatile choroidal blood flow [23, 47±49] but the steady component of choroidal blood flow cannot be assessed using this method. We cannot exclude entirely changes in flow pulsatility in the choroid during insulin and glucose infusion or both. These changes are assumed to be, however, small if systemic blood pressure and heart rate do not change [47] . In addition, care must be taken when extrapolating the present results to the microvasculature. In our study indices of organ blood flow were measured for the eye and kidney and no direct information on the microvasculature in the vascular beds was obtained. There is, however, evidence that the insulin induced increase in perfusion is accompanied by capillary recruitment in the leg muscle [50] . Our study does not indicate if this is also the case in the ocular and renal circulation.
To conclude, our data show that glucose and insulin have additive vasodilator effects on the eye and kidney. Whether this observation is related to increased regional perfusion in patients with diabetes requires longitudinal studies in patients with Type I diabetes.
